<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ment Health Clin</journal-id><journal-id journal-id-type="iso-abbrev">Ment Health Clin</journal-id><journal-id journal-id-type="publisher-id">mhcl</journal-id><journal-title-group><journal-title>The Mental Health Clinician</journal-title></journal-title-group><issn pub-type="epub">2168-9709</issn><publisher><publisher-name>College of Psychiatric &#x00026; Neurologic Pharmacists</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30842917</article-id><article-id pub-id-type="pmc">6398358</article-id><article-id pub-id-type="doi">10.9740/mhc.2019.03.093</article-id><article-id pub-id-type="sici">mhcl-09-02-09</article-id><article-categories><subj-group subj-group-type="heading"><subject>Literature Review</subject></subj-group></article-categories><title-group><article-title>Review of the many faces of synthetic cannabinoid toxicities</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Alipour</surname><given-names>Azita</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4455-0525</contrib-id><degrees>PharmD, BCPP, BCGP</degrees></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Puja Baldev</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1756-9135</contrib-id><degrees>PharmD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shabbir</surname><given-names>Zaheera</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2068-7757</contrib-id><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gabrielson</surname><given-names>Stephen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9420-4466</contrib-id><degrees>MSLIS, AHIP</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib><aff id="aff2">
<label>2&#x02009;</label>Assistant Professor, Department of Pharmacy Practice, Marshall B. Ketchum University College of Pharmacy, Fullerton, California
</aff><aff id="aff3">
<label>3&#x02009;</label>PharmD Candidate, University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois
</aff><aff id="aff4">
<label>4&#x02009;</label>Pharmacy Librarian, Marshall B. Ketchum University, MB Ketchum Memorial Library, Fullerton, California
</aff></contrib-group><author-notes><corresp id="cor1"><sup>1</sup>&#x02009; Assistant Professor, Department of Pharmacy Practice, Marshall B. Ketchum University, College of Pharmacy, Fullerton, California, <email>aalipour@ketchum.edu</email></corresp><fn id="n101" fn-type="COI-statement"><p><bold>Disclosures:</bold> The authors of this article have no conflicts of interest to disclose.</p></fn></author-notes><pub-date pub-type="collection"><month>3</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>1</day><month>3</month><year>2019</year></pub-date><volume>9</volume><issue>2</issue><fpage>93</fpage><lpage>99</lpage><permissions><copyright-statement>&#x000a9; 2019 CPNP. The Mental Health Clinician is a publication of the College of Psychiatric and Neurologic Pharmacists.</copyright-statement><copyright-year>2019</copyright-year><license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Introduction</title><p>Synthetic cannabinoids (SCs) are psychoactive substances that are gaining popularity for their availability and lack of detection by standardized drug tests. Although some users may perceive SCs as safer alternatives to marijuana, some SCs are more potent and result in more severe toxicities.</p></sec><sec id="st2"><title>Methods</title><p>A search of the literature was conducted in the PubMed and SciFinder databases. Results in PubMed were limited to human studies, and only articles in English were included.</p></sec><sec id="st3"><title>Results</title><p>Review of the literature illustrates the hazards associated with SC use. A range of severe toxicities affecting numerous systems has been identified, such as arrhythmias, myocardial infarction, sudden cardiac death, psychosis, suicidal ideation, seizures, acute tubular necrosis, and intracranial hemorrhage. Additionally, a recent outbreak of coagulopathies and at least 4 associated deaths due to SCs tainted with brodifacoum have been reported.</p></sec><sec id="st4"><title>Discussion</title><p>Synthetic cannabinoids may be perceived as a safer alternative to marijuana; however, SCs can be more potent at the cannabinoid receptors and in turn have greater toxicities. Limited information is available on the metabolism of SCs; however, cytochrome P450 pathways may be involved, which could result in drug interactions and unpredicted adverse effects. Toxicity with SC use is not just related to its effects, but also to additives that may taint these products and enhance their effects. Health care providers should be aware of the range of toxicities related to SC use, and tainted products such as these agents are not detected on routine drug screens.</p></sec></abstract><kwd-group><kwd>synthetic marijuana</kwd><kwd>synthetic cannabis</kwd><kwd>synthetic cannabinoids</kwd><kwd>cannabinoids</kwd><kwd>designer drugs</kwd><kwd>street drugs</kwd><kwd>toxicity</kwd><kwd>hemorrhage</kwd><kwd>bleeding</kwd><kwd>K2</kwd><kwd>spice</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>Citation</meta-name><meta-value><bold>How to cite:</bold> Alipour A, Patel PB, Shabbir Z, Gabrielson S. Review of the many faces of synthetic cannabinoid toxicities. Ment Health Clin [Internet].</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Synthetic cannabinoids (SCs) available commercially by names such as spice and K2 are man-made compounds that bind to the G protein&#x02013;coupled cannabinoid receptors (CB<sub>1</sub> and CB<sub>2</sub>).<xref rid="i2168-9709-9-2-93-b01" ref-type="bibr">1</xref>,<xref rid="i2168-9709-9-2-93-b02" ref-type="bibr">2</xref> The CB<sub>1</sub> and CB<sub>2</sub> receptors have been found to affect multiple systems in the human body, including but not limited to the central nervous, respiratory, cardiovascular, and immune systems.<xref rid="i2168-9709-9-2-93-b02" ref-type="bibr">2</xref></p><p>The structural features of many SCs have demonstrated higher binding affinities to the CB<sub>1</sub> and CB<sub>2</sub> receptors when compared to tetrahydrocannabinol (THC), the active ingredient in cannabis.<xref rid="i2168-9709-9-2-93-b03" ref-type="bibr">3</xref>-<xref rid="i2168-9709-9-2-93-b06" ref-type="bibr">6</xref> Tetrahydrocannabinol displays partial agonism at the CB<sub>1</sub> and CB<sub>2</sub> receptors, whereas SCs may be full agonists at these receptors.<xref rid="i2168-9709-9-2-93-b07" ref-type="bibr">7</xref>,<xref rid="i2168-9709-9-2-93-b08" ref-type="bibr">8</xref> Additionally, SC metabolites have stronger affinities for the CB<sub>1</sub> and CB<sub>2</sub> receptors compared to THC, which may result in distinct effects.<xref rid="i2168-9709-9-2-93-b08" ref-type="bibr">8</xref> Continued binding of metabolites to the CB<sub>1</sub> receptor may be responsible for the greater potency and longer duration of pharmacologic effects as well as toxicity.<xref rid="i2168-9709-9-2-93-b07" ref-type="bibr">7</xref></p><p>Many SC compounds and cannabinoid structural classes have been placed into Schedule I of the Controlled Substances Act, following signed legislation of the Food and Drug Administration Safety and Innovation Act of 2012 by President Obama.<xref rid="i2168-9709-9-2-93-b09" ref-type="bibr">9</xref>,<xref rid="i2168-9709-9-2-93-b10" ref-type="bibr">10</xref> Schedule I substances, according to the US Drug Enforcement Administration,<xref rid="i2168-9709-9-2-93-b11" ref-type="bibr">11</xref> are defined as &#x0201c;drugs with no currently accepted medical use and a high potential for abuse.&#x0201d; However, new SCs are continuously being created, and therefore, some of these products may not be classified as Schedule I substances currently.<xref rid="i2168-9709-9-2-93-b10" ref-type="bibr">10</xref>,<xref rid="i2168-9709-9-2-93-b12" ref-type="bibr">12</xref></p><p>Synthetic cannabinoids constitute 1 of the largest groups of psychoactive substances and were originally manufactured for experimentation purposes in 1965.<xref rid="i2168-9709-9-2-93-b02" ref-type="bibr">2</xref>,<xref rid="i2168-9709-9-2-93-b03" ref-type="bibr">3</xref>,<xref rid="i2168-9709-9-2-93-b13" ref-type="bibr">13</xref> These compounds, specifically spice, gained popularity for their psychoactive properties in the mid-2000s.<xref rid="i2168-9709-9-2-93-b13" ref-type="bibr">13</xref> Synthetic cannabinoid products were available via the Internet as well as in specialty smoking shops and convenience stores.<xref rid="i2168-9709-9-2-93-b06" ref-type="bibr">6</xref> Synthetic cannabinoids are usually incorporated into fragrances, potpourri, and incense with a warning label &#x0201c;not for human consumption.&#x0201d;<sup>6(p526)</sup> It is important to note SCs are not a part of standard drug tests.<xref rid="i2168-9709-9-2-93-b14" ref-type="bibr">14</xref> However, data from US poison control centers indicate calls regarding SC exposures more than doubled from 2906 calls in 2010 to 6959 in 2011.<xref rid="i2168-9709-9-2-93-b15" ref-type="bibr">15</xref></p><p>Serious adverse health events linked to the ingestion of SCs have been reported.<xref rid="i2168-9709-9-2-93-b05" ref-type="bibr">5</xref> Reported SC toxicities include but are not limited to agitation, anxiety, drowsiness, tachycardia, hypertension, nausea, and vomiting as well as other serious adverse clinical effects, such as psychosis, stroke, seizures, and cardiac complications.<xref rid="i2168-9709-9-2-93-b04" ref-type="bibr">4</xref>,<xref rid="i2168-9709-9-2-93-b05" ref-type="bibr">5</xref> Additionally, between March and April of 2018, there was an outbreak of severe bleeding events in patients who had ingested SC products tainted with brodifacoum (a rodenticide) with a majority of cases occurring in Illinois.<xref rid="i2168-9709-9-2-93-b16" ref-type="bibr">16</xref>,<xref rid="i2168-9709-9-2-93-b17" ref-type="bibr">17</xref> Synthetic cannabinoid products have an unpredictable nature due to unregulated manufacturing processes and variability of ingredients.<xref rid="i2168-9709-9-2-93-b10" ref-type="bibr">10</xref> Considering the diverse toxicity profile of these compounds, it is important to identify the scope and severity of the public health threat posed by SC use as described in the literature, including recent bleeding events with tainted SC products. To our knowledge, this is the first published review of SC toxicities to include recent coagulopathies associated with tainted SC use.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>A literature search was conducted in the PubMed MEDLINE and SciFinder databases. Results in PubMed were limited to human studies, and only English articles were included. No database filters were used for publication dates; however, articles from 2012 to 2018 were selected for this review. MeSH (medical subject headings) terms used in the search were <italic>cannabinoids</italic>, <italic>designer drugs</italic>, and <italic>street drugs</italic>. Keywords used were <italic>synthetic marijuana</italic>, <italic>synthetic cannabinoids</italic>, and other related terms. <italic>K2</italic> and <italic>spice</italic> were also used as keywords in the search to include well-known synthetic marijuana brands. Keywords and MeSH terms for <italic>bleeding</italic> in relation to adverse effects of SCs were also used.</p><p>A second search of the literature was completed in the SciFinder database. Due to SciFinder's recommended method of searching, the phrase <italic>toxicity of synthetic cannabinoids</italic> was used as the main search query to help the database identify the major concepts of <italic>toxicity</italic> and <italic>synthetic cannabinoids</italic>. Because SciFinder also searches MEDLINE, results were limited to the CAplus index in SciFinder, which is a comprehensive database of the chemistry literature that includes resources not covered in MEDLINE.</p></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Cardiac Effects</title><p>Acute cardiac toxicities are relatively common among SC users presenting to medical centers for emergency care.<xref rid="i2168-9709-9-2-93-b05" ref-type="bibr">5</xref>,<xref rid="i2168-9709-9-2-93-b18" ref-type="bibr">18</xref>,<xref rid="i2168-9709-9-2-93-b19" ref-type="bibr">19</xref> The presence of tachycardia is 1 of the most commonly reported findings after ingesting SCs.<xref rid="i2168-9709-9-2-93-b05" ref-type="bibr">5</xref>,<xref rid="i2168-9709-9-2-93-b20" ref-type="bibr">20</xref> Supraventricular tachycardia with heart rates as high as 172 beats per minutes were reported in a 24-year-old after ingestion of e-cigarette fluid mixed with SCs.<xref rid="i2168-9709-9-2-93-b21" ref-type="bibr">21</xref></p><p>In addition, acute myocardial infarction (MI) has been associated with SC use in adolescents and adults.<xref rid="i2168-9709-9-2-93-b22" ref-type="bibr">22</xref> A 15-year-old with a 30-month history of SC abuse presented with ST segment elevation MI and stroke.<xref rid="i2168-9709-9-2-93-b23" ref-type="bibr">23</xref> Myocardial infarction was also reported in the case of a 39-year-old who presented with left-side chest pain and who subsequently collapsed with ventricular fibrillation.<xref rid="i2168-9709-9-2-93-b12" ref-type="bibr">12</xref> The individual was noted to have ST segment elevation and elevated troponin.<xref rid="i2168-9709-9-2-93-b12" ref-type="bibr">12</xref></p><p>Cardiovascular fatalities associated with SC use have also been described in the literature. Cases include sudden cardiac death in a 22-year-old after smoking SC (MDMB-CHMICA) and fatal coronary artery thrombosis in a 41-year-old after using the SC ADB-FUBINACA.<xref rid="i2168-9709-9-2-93-b01" ref-type="bibr">1</xref>,<xref rid="i2168-9709-9-2-93-b24" ref-type="bibr">24</xref></p></sec><sec id="s3b"><title>Hematological Effects</title><p>In March of 2018, the Illinois Poison Center informed the Illinois Department of Public Health of cases of high international normalized ratios and unexplained bleeding in emergency departments over the past 2 weeks in individuals who had used SC in the past 3 days.<xref rid="i2168-9709-9-2-93-b25" ref-type="bibr">25</xref> This prompted an investigation by health and law enforcement agencies. Following this investigation, 155 cases were identified: 4 fatalities occurred from major bleeding, 147 individuals required hospitalization, and 8 required only emergency department care.<xref rid="i2168-9709-9-2-93-b25" ref-type="bibr">25</xref> All individuals had high international normalized ratios and reported at least 1 bleeding site.<xref rid="i2168-9709-9-2-93-b25" ref-type="bibr">25</xref> Hematuria was the most commonly occurring sign.<xref rid="i2168-9709-9-2-93-b25" ref-type="bibr">25</xref> Clinical specimens from 81 subjects with probable or confirmed cases tested positive for brodifacoum, which is used in rodenticides as a long-acting vitamin K antagonist.<xref rid="i2168-9709-9-2-93-b25" ref-type="bibr">25</xref> Three case reports were published after the outbreak describing coagulopathy related to K2 tainted with brodifacoum; additional information on these cases<xref rid="i2168-9709-9-2-93-b26" ref-type="bibr">26</xref>,<xref rid="i2168-9709-9-2-93-b27" ref-type="bibr">27</xref> can be found in <xref rid="i2168-9709-9-2-93-t01" ref-type="table">Table 1</xref>.</p><table-wrap id="i2168-9709-9-2-93-t01" content-type="1col" orientation="portrait" position="float"><label>TABLE 1</label><caption><p>Bleeding with use of synthetic cannabinoids tainted with brodifacoum</p></caption><table frame="hsides" rules="none"><colgroup span="1"><col id="tb1col1" align="left" charoff="0" char="" span="1"/><col id="tb1col2" align="left" charoff="0" char="" span="1"/><col id="tb1col3" align="left" charoff="0" char="" span="1"/></colgroup><thead><tr><td align="center" rowspan="1" colspan="1"><hr/></td><td rowspan="1" colspan="1"><bold>Panigrahi et al<sup>26</sup></bold><hr/></td><td rowspan="1" colspan="1"><bold>Hussain et al<sup>27</sup></bold><hr/></td></tr></thead><tbody><tr><td rowspan="1" colspan="1">State, country</td><td rowspan="1" colspan="1">Maryland, United States</td><td rowspan="1" colspan="1">Illinois, United States</td></tr><tr><td rowspan="2" colspan="1">Patient demographics</td><td rowspan="1" colspan="1">Case 1: 51-year-old male</td><td rowspan="2" colspan="1">38-year-old male</td></tr><tr><td rowspan="1" colspan="1">Case 2: 39-year-old female</td></tr><tr><td rowspan="2" colspan="1">Clinical presentation</td><td rowspan="1" colspan="1">Case 1: Bruising of thigh and elbow accompanied by leg swelling and severe back pain. Return visit to ED 2 d later showed worsening hematuria, bruising, leg pain, and swelling.</td><td rowspan="2" colspan="1">Hemoptysis and dark urine for 2 d prior to presenting to the ED</td></tr><tr><td rowspan="1" colspan="1">Case 2: Stomach and extremities had spontaneous bruising, hematuria, hemoptysis, epitaxis, and abdominal pain that radiated to the back.</td></tr><tr><td rowspan="2" colspan="1">Radiologic findings</td><td rowspan="1" colspan="1">Case 1: Contrast-enhanced CT image: bilateral hemorrhagic, pyelitis, and ureteritis</td><td rowspan="2" colspan="1">None listed</td></tr><tr><td rowspan="1" colspan="1">Case 2: CT of abdomen and pelvis: hemorrhagic pyelitis/ureteritis</td></tr><tr><td rowspan="2" colspan="1">International normalized ratio</td><td rowspan="1" colspan="1">Case 1: &#x0003e;12.2 (greater than measurable threshold)</td><td rowspan="2" colspan="1">&#x0003e;10</td></tr><tr><td rowspan="1" colspan="1">Case 2: Greater than measurable threshold</td></tr><tr><td rowspan="2" colspan="1">Toxicology screen</td><td rowspan="1" colspan="1">Case 1: Negative for cannabinoid; positive for opiates (on opiate for back pain)</td><td rowspan="2" colspan="1">Positive for brodifacoum in the serum</td></tr><tr><td rowspan="1" colspan="1">Case 2: Negative for cannabinoid, positive for brodifacoum</td></tr><tr><td rowspan="2" colspan="1">Synthetic cannabinoid compound</td><td rowspan="1" colspan="1">Case 1: K2</td><td rowspan="2" colspan="1">K2</td></tr><tr><td rowspan="1" colspan="1">Case 2: Per study authors, likely the same source as her fianc&#x000e9; in case 1</td></tr><tr><td rowspan="2" colspan="1">Treatments received</td><td rowspan="1" colspan="1">Both patients received intravenous vitamin K &#x000d7; 1 dose, then oral vitamin K while inpatient and subsequently discharged on oral vitamin K.</td><td rowspan="2" colspan="1">Received intravenous vitamin K followed by oral vitamin K, which was recommended by poison control to be continued on discharge for at least 1 mo</td></tr><tr><td rowspan="1" colspan="1">Patient in case 1 received 1 unit of fresh-frozen plasma while in the hospital due to severe coagulopathy</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><p>CT = computed tomography; ED = emergency department.</p></fn></table-wrap-foot></table-wrap><p>Aside from the recent outbreak of severe bleeding occurring mostly in Illinois and also in other states, reports on coagulopathies as adverse effects have been limited. Other reports of bleeding have included the development of a right frontal intracerebral hematoma in a habitual user of spice.<xref rid="i2168-9709-9-2-93-b28" ref-type="bibr">28</xref> In addition, published reports<xref rid="i2168-9709-9-2-93-b28" ref-type="bibr">28</xref>,<xref rid="i2168-9709-9-2-93-b29" ref-type="bibr">29</xref> have demonstrated instances of intracranial hemorrhage following use of spice.</p></sec><sec id="s3c"><title>Neurologic Effects</title><p>The possibility that SC abuse may cause neurotoxicity is well documented in the literature.<xref rid="i2168-9709-9-2-93-b30" ref-type="bibr">30</xref> In a recent case report,<xref rid="i2168-9709-9-2-93-b31" ref-type="bibr">31</xref> a 25-year-old presented with symptoms of stroke the morning after smoking an SC-containing product called freeze. An extensive diagnostic workup was conducted, including magnetic resonance imaging, which revealed acute ischemic infarction.<xref rid="i2168-9709-9-2-93-b31" ref-type="bibr">31</xref> Further examination via magnetic resonance angiography and ultrasound showed occlusion of the proximal right middle cerebral artery.<xref rid="i2168-9709-9-2-93-b31" ref-type="bibr">31</xref> Additionally, 2 cases of ischemic stroke within hours of first SC use were reported, suggesting a possible association.<xref rid="i2168-9709-9-2-93-b32" ref-type="bibr">32</xref></p><p>Seizures are another severe adverse effect occurring with SCs, but they are rarely reported with cannabis use given THC's weak affinity for the cannabinoid receptors.<xref rid="i2168-9709-9-2-93-b33" ref-type="bibr">33</xref> The exact mechanism of SC-induced seizures is currently unknown.<xref rid="i2168-9709-9-2-93-b33" ref-type="bibr">33</xref> However, it is postulated strong binding of the CB<sub>1</sub> receptors may be involved.<xref rid="i2168-9709-9-2-93-b33" ref-type="bibr">33</xref> In a prospective observation study, Hermanns-Clausen et al<xref rid="i2168-9709-9-2-93-b18" ref-type="bibr">18</xref> conducted a toxicological analysis of individuals (n&#x02009;=&#x02009;44) presenting to emergency departments after the ingestion of SCs. A high frequency of generalized seizures (n&#x02009;=&#x02009;12, 27%) was seen in patients after using MDMB-CHMICA and/or AB-CHMINACA.<xref rid="i2168-9709-9-2-93-b18" ref-type="bibr">18</xref> In addition, Schep et al<xref rid="i2168-9709-9-2-93-b04" ref-type="bibr">4</xref> described a case in which a 23-year-old experienced seizure activity 6 hours after smoking K2.</p></sec><sec id="s3d"><title>Psychiatric Effects</title><p>Synthetic cannabinoids have been associated in case reports with numerous psychiatric adverse effects, such as anxiety, agitation, suicidal ideation, depersonalization, dissociation, and psychosis.<xref rid="i2168-9709-9-2-93-b06" ref-type="bibr">6</xref>,<xref rid="i2168-9709-9-2-93-b34" ref-type="bibr">34</xref>,<xref rid="i2168-9709-9-2-93-b35" ref-type="bibr">35</xref> Synthetic cannabinoids often result in more amplified neuropsychiatric effects than THC due to their considerably greater potency.<xref rid="i2168-9709-9-2-93-b36" ref-type="bibr">36</xref> Acute intoxication with SCs may result in psychotic-like symptoms, including disorganized behavior, hallucinations, and paranoia, which often last longer than anxiety or motor symptoms.<xref rid="i2168-9709-9-2-93-b10" ref-type="bibr">10</xref> In a multicenter cohort analysis, Monte et al<xref rid="i2168-9709-9-2-93-b37" ref-type="bibr">37</xref> identified 353 cases of SC toxicity from the ToxIC registry, which contains clinical information relating to cases requiring care by medical toxicologists within the United States. In this analysis,<xref rid="i2168-9709-9-2-93-b37" ref-type="bibr">37</xref> toxic psychosis, delirium, and agitation were the most frequently presenting signs. In a systematic review by Tait et al,<xref rid="i2168-9709-9-2-93-b05" ref-type="bibr">5</xref> agitation was identified as the most common presenting psychiatric effect. Overall, although there is a lack of controlled studies of SCs, reports indicate SCs may trigger psychotic symptoms in subjects with no previous history of psychosis and reemergence of psychosis in vulnerable patients.<xref rid="i2168-9709-9-2-93-b10" ref-type="bibr">10</xref></p><p>Jaenicke et al<xref rid="i2168-9709-9-2-93-b35" ref-type="bibr">35</xref> reviewed cases of SC use as detected from blood samples in criminal and traffic offenses. The authors<xref rid="i2168-9709-9-2-93-b35" ref-type="bibr">35</xref> identified 12 cases of SC use with 10 of the cases involving multidrug consumption. Alcohol and cannabis were often co-occurring drugs with SCs.<xref rid="i2168-9709-9-2-93-b35" ref-type="bibr">35</xref> One person experiencing paranoia before cannabinoid agonist use was noted to have worsened paranoia following consumption.<xref rid="i2168-9709-9-2-93-b35" ref-type="bibr">35</xref> The subject had blood samples positive for SC (JWH-122) and cannabis (THC) as well as a cannabis metabolite (11-nor-9-carboxy-&#x00394;9-tetrahydrocannabinol).<xref rid="i2168-9709-9-2-93-b35" ref-type="bibr">35</xref> Dopaminergic pathways interacting with the endocannabinoid system can result in psychosis.<xref rid="i2168-9709-9-2-93-b33" ref-type="bibr">33</xref> This may explain episodes of psychosis and early schizophrenia symptom onset that may develop after cannabis use.<xref rid="i2168-9709-9-2-93-b33" ref-type="bibr">33</xref></p></sec><sec id="s3e"><title>Renal Effects</title><p>Case reports and case series suggest an association between the use of SCs and the development of acute kidney injury (AKI).<xref rid="i2168-9709-9-2-93-b36" ref-type="bibr">36</xref>,<xref rid="i2168-9709-9-2-93-b38" ref-type="bibr">38</xref> A 22-year-old with no previous medical conditions presented 3 days after smoking SC with flank pain, nausea, vomiting, and AKI.<xref rid="i2168-9709-9-2-93-b36" ref-type="bibr">36</xref> Renal ultrasound demonstrated no acute abnormalities; however, acute tubular necrosis was detected on renal biopsy.<xref rid="i2168-9709-9-2-93-b36" ref-type="bibr">36</xref> After receiving supportive management, renal function improved and serum creatinine decreased from 7.05 mg/dL to 2.5 mg/dL before discharge.<xref rid="i2168-9709-9-2-93-b36" ref-type="bibr">36</xref> The authors then summarized 20 other cases of AKI associated with SC abuse.<xref rid="i2168-9709-9-2-93-b36" ref-type="bibr">36</xref> Of the 20 cases identified, 19 of the 20 were men, and their ages ranged from 15 to 33 years old.<xref rid="i2168-9709-9-2-93-b36" ref-type="bibr">36</xref> They presented with nausea, vomiting, abdominal pain, diarrhea, flank pain, back pain, and/or anuria, of which nausea, vomiting, and abdominal pain were the most common.<xref rid="i2168-9709-9-2-93-b36" ref-type="bibr">36</xref> Of the 20, 9 developed acute tubular necrosis, acute interstitial nephritis was identified in 3, and dialysis was required in 5.<xref rid="i2168-9709-9-2-93-b36" ref-type="bibr">36</xref></p><p>Buser et al<xref rid="i2168-9709-9-2-93-b38" ref-type="bibr">38</xref> published a case series on individuals who developed AKI (defined as a creatinine &#x0003e;1.3 mg/dL) after using SCs. Included individuals had to be between the ages of 13 and 40 years of age &#x0201c;without known preexisting renal disease.&#x0201d;<sup>38(p665)</sup> Based on this criteria, 9 men were identified with ages ranging between 15 and 27 years of age and presented with nausea, vomiting, abdominal pain, or back pain. All individuals required hospitalization, of which 1 needed dialysis. The authors<xref rid="i2168-9709-9-2-93-b38" ref-type="bibr">38</xref> reviewed laboratory data and patient history and did not find any other causes for the development of AKI.</p></sec></sec><sec id="s4"><title>Discussion</title><p>Synthetic cannabinoids have been advertised as legal or harmless alternatives to marijuana, leading to the misconception of the safety of these substances, when, in fact, severe adverse effects and need for emergency medical treatment are more likely to occur with SCs than cannabis.<xref rid="i2168-9709-9-2-93-b05" ref-type="bibr">5</xref>,<xref rid="i2168-9709-9-2-93-b07" ref-type="bibr">7</xref>,<xref rid="i2168-9709-9-2-93-b10" ref-type="bibr">10</xref>,<xref rid="i2168-9709-9-2-93-b37" ref-type="bibr">37</xref> According to Martinotti et al,<xref rid="i2168-9709-9-2-93-b07" ref-type="bibr">7</xref> the risk of an emergency room visit is approximately 30-fold higher with SC than with cannabis. The difference in severe adverse effects highlights the increased safety risk as agitation and cardiotoxicity are, respectively, 3.8 and 9.2 times more likely to occur with SCs than traditional cannabis.<xref rid="i2168-9709-9-2-93-b07" ref-type="bibr">7</xref> Synthetic cannabinoids are full agonists with higher potency when compared to the partial agonist THC at the CB<sub>1</sub> and CB<sub>2</sub> receptors, which may account for their greater toxicities.<xref rid="i2168-9709-9-2-93-b39" ref-type="bibr">39</xref></p><p>The literature<xref rid="i2168-9709-9-2-93-b05" ref-type="bibr">5</xref>,<xref rid="i2168-9709-9-2-93-b06" ref-type="bibr">6</xref>,<xref rid="i2168-9709-9-2-93-b15" ref-type="bibr">15</xref>,<xref rid="i2168-9709-9-2-93-b37" ref-type="bibr">37</xref>,<xref rid="i2168-9709-9-2-93-b40" ref-type="bibr">40</xref> indicates a range of adverse effects associated with SC use (see <xref rid="i2168-9709-9-2-93-t02" ref-type="table">Table 2</xref>) from tachycardia to more severe cases, such as MI, stroke, psychosis, seizures, and associated deaths. A 2016 systematic review by Tait et al<xref rid="i2168-9709-9-2-93-b05" ref-type="bibr">5</xref> identified adverse events due to SC use. Nausea, agitation, and tachycardia presented most often in young men and generally resolved with supportive care.<xref rid="i2168-9709-9-2-93-b05" ref-type="bibr">5</xref> Serious adverse events and related deaths were less common.<xref rid="i2168-9709-9-2-93-b05" ref-type="bibr">5</xref> Monte et al<xref rid="i2168-9709-9-2-93-b37" ref-type="bibr">37</xref> reported agitation, toxic psychosis, and delirium as the most commonly occurring symptoms in their multicenter analysis. Although treatment is not the focus of this review, caution should be exercised when treating psychosis related to SC use as antipsychotic treatment may decrease the seizure threshold, and SC use has been associated with seizures.<xref rid="i2168-9709-9-2-93-b41" ref-type="bibr">41</xref> Although there is limited data on the pharmacology of SCs, literature<xref rid="i2168-9709-9-2-93-b10" ref-type="bibr">10</xref>,<xref rid="i2168-9709-9-2-93-b36" ref-type="bibr">36</xref>,<xref rid="i2168-9709-9-2-93-b42" ref-type="bibr">42</xref>,<xref rid="i2168-9709-9-2-93-b43" ref-type="bibr">43</xref> suggests possible involvement of the cytochrome P450 system and possible unforeseen drug-drug interactions and toxicity. Cytochrome P450 (CYP) metabolism of the SCs JWH-018 and AM2201 was found to be primarily by CYP2C9 and CYP1A2.<xref rid="i2168-9709-9-2-93-b43" ref-type="bibr">43</xref></p><table-wrap id="i2168-9709-9-2-93-t02" content-type="1col" orientation="portrait" position="float"><label>TABLE 2</label><caption><p>Reported effects with synthetic cannabinoid intoxication<xref rid="i2168-9709-9-2-93-b05" ref-type="bibr">5</xref>,<xref rid="i2168-9709-9-2-93-b06" ref-type="bibr">6</xref>,<xref rid="i2168-9709-9-2-93-b15" ref-type="bibr">15</xref>,<xref rid="i2168-9709-9-2-93-b37" ref-type="bibr">37</xref>,<xref rid="i2168-9709-9-2-93-b41" ref-type="bibr">41</xref>,<xref rid="i2168-9709-9-2-93-b45" ref-type="bibr">45</xref></p></caption><table frame="hsides" rules="none"><colgroup span="1"><col id="tb2col1" align="left" charoff="0" char="" span="1"/><col id="tb2col2" align="left" charoff="0" char="" span="1"/></colgroup><thead><tr><td align="center" rowspan="1" colspan="1"><bold>System</bold><hr/></td><td rowspan="1" colspan="1"><bold>Synthetic Cannabinoid Intoxication Effects</bold><hr/></td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Cardiac</td><td rowspan="1" colspan="1">Tachycardia, supraventricular tachycardia, ventricular fibrillation, myocardial infarction, sudden cardiac death, coronary arterial thrombosis</td></tr><tr><td rowspan="1" colspan="1">Hematological</td><td rowspan="1" colspan="1">Immune thrombocytopenia, intracranial hemorrhage, coagulopathy</td></tr><tr><td rowspan="1" colspan="1">Neurological</td><td rowspan="1" colspan="1">Dizziness, drowsiness, tremor, altered mental status, seizure, acute ischemic infarction</td></tr><tr><td rowspan="1" colspan="1">Psychiatric</td><td rowspan="1" colspan="1">Agitation, anxiety, paranoia, psychosis, suicidal ideation, delirium, dissociation, depersonalization, hallucinations, disorganized behavior</td></tr><tr><td rowspan="1" colspan="1">Renal</td><td rowspan="1" colspan="1">Acute kidney injury, acute tubular necrosis</td></tr><tr><td rowspan="1" colspan="1">Other</td><td rowspan="1" colspan="1">Nausea, vomiting, rhabdomyolysis, hyperthermia</td></tr></tbody></table></table-wrap><p>Manufacturing of SCs is not regulated, leading to variation in components and amounts in the variety of products available.<xref rid="i2168-9709-9-2-93-b41" ref-type="bibr">41</xref> Therefore, in addition to concern for possible toxicities directly associated with SCs, additional toxicity concerns exist due to dangerous substances that may have been incorporated into these products.<xref rid="i2168-9709-9-2-93-b41" ref-type="bibr">41</xref> Synthetic cannabinoids may be mixed with other psychoactive substances, such as bath salts or ecstasy/Molly by dealers to increase sales.<xref rid="i2168-9709-9-2-93-b41" ref-type="bibr">41</xref> The recent outbreak in the United States of severe bleeding events leading to at least 4 deaths due to SCs tainted with the rodenticide, brodifacoum, underscores these dangers.<xref rid="i2168-9709-9-2-93-b16" ref-type="bibr">16</xref>,<xref rid="i2168-9709-9-2-93-b25" ref-type="bibr">25</xref>,<xref rid="i2168-9709-9-2-93-b27" ref-type="bibr">27</xref>,<xref rid="i2168-9709-9-2-93-b41" ref-type="bibr">41</xref> As a super warfarin, brodifacoum has been used by humans for intentional harm.<xref rid="i2168-9709-9-2-93-b27" ref-type="bibr">27</xref> Compared to warfarin, brodifacoum is up to 100 times as potent and has a half-life that is at least 9.6 times longer (16 days vs 40 hours).<xref rid="i2168-9709-9-2-93-b27" ref-type="bibr">27</xref> Because of the very long half-life, bleeding may last up to months after poisoning.<xref rid="i2168-9709-9-2-93-b27" ref-type="bibr">27</xref> Brodifacoum may be stored in and released from lipids over a long time period.<xref rid="i2168-9709-9-2-93-b27" ref-type="bibr">27</xref> It is suggested that the storage of brodifacoum prolongs and enhances the high of these products, which may explain its presence in SCs.<xref rid="i2168-9709-9-2-93-b27" ref-type="bibr">27</xref></p><p>Phytonadione (vitamin K1) has been used to treat these individuals, but the optimal dosage is yet to be determined.<xref rid="i2168-9709-9-2-93-b16" ref-type="bibr">16</xref> Phytonadione doses of up to 200 mg/d have been required during the hospitalization of some individuals.<xref rid="i2168-9709-9-2-93-b16" ref-type="bibr">16</xref> Difficulty arose when outpatient doses were required at discharge due to the high cost of this medication and pharmacies not stocking adequate supplies.<xref rid="i2168-9709-9-2-93-b16" ref-type="bibr">16</xref> Although prescription phytonadione is costly, individuals should be warned not to use phytonadione dietary supplements as they do not provide enough phytonadione to adequately treat coagulopathy.<xref rid="i2168-9709-9-2-93-b16" ref-type="bibr">16</xref> More severe bleeding may necessitate the use of fresh-frozen plasma or prothrombin complex concentrate.<xref rid="i2168-9709-9-2-93-b16" ref-type="bibr">16</xref></p><p>The outbreak of severe bleeding events also highlights the need for better detection and awareness of SCs as they may not be identified on standard drug screenings.<xref rid="i2168-9709-9-2-93-b05" ref-type="bibr">5</xref> Davies et al<xref rid="i2168-9709-9-2-93-b44" ref-type="bibr">44</xref> describe the challenges of identifying SCs but mention that tandem mass spectrometry, accurate mass technique, and simple method modification may be useful. The lack of readily available methods to detect these compounds coupled with the variability of their composition may limit our ability to further quantify the prevalence of toxicities.<xref rid="i2168-9709-9-2-93-b05" ref-type="bibr">5</xref> When patients present to emergency departments after ingesting SCs with behavioral adverse effects or severe illness, SC use is not immediately discovered.<xref rid="i2168-9709-9-2-93-b05" ref-type="bibr">5</xref> Therefore, health care professionals should be aware of life-threatening toxicities of SCs.<xref rid="i2168-9709-9-2-93-b05" ref-type="bibr">5</xref></p></sec></body><back><ref-list><title>References</title><ref id="i2168-9709-9-2-93-b01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shanks</surname><given-names>KG</given-names></name><name name-style="western"><surname>Clark</surname><given-names>W</given-names></name><name name-style="western"><surname>Behonick</surname><given-names>G</given-names></name></person-group><article-title>Death associated with the use of the synthetic cannabinoid ADB-FUBINACA</article-title><source>J Anal Toxicol</source><year>2016</year><volume>40</volume><issue>3</issue><fpage>236</fpage><lpage>9</lpage><comment>DOI: 10.1093/jat/bkv142 PubMed PMID: 26755539 PubMed Central PMCID: </comment><pub-id pub-id-type="doi">10.1093/jat/bkv142</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26755539">26755539</ext-link><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885918">PMC4885918</ext-link><comment> PubMed PMID: 26755539 PubMed Central PMCID: PMC4885918</comment><pub-id pub-id-type="pmid">26755539</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abouchedid</surname><given-names>R</given-names></name><name name-style="western"><surname>Ho</surname><given-names>JH</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>S</given-names></name><name name-style="western"><surname>Dines</surname><given-names>A</given-names></name><name name-style="western"><surname>Archer</surname><given-names>JRH</given-names></name><name name-style="western"><surname>Wood</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Acute toxicity associated with use of 5F-derivations of synthetic cannabinoid receptor agonists with analytical confirmation</article-title><source>J Med Toxicol</source><year>2016</year><volume>12</volume><issue>4</issue><fpage>396</fpage><lpage>401</lpage><comment>DOI: 10.1007/s13181-016-0571-7 PubMed PMID: 27456262 PubMed Central PMCID: </comment><pub-id pub-id-type="doi">10.1007/s13181-016-0571-7</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/27456262">27456262</ext-link><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135680">PMC5135680</ext-link><comment> PubMed PMID: 27456262 PubMed Central PMCID: PMC5135680</comment><pub-id pub-id-type="pmid">27456262</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adamowicz</surname><given-names>P</given-names></name></person-group><article-title>Fatal intoxication with synthetic cannabinoid MDMB-CHMICA</article-title><source>Forensic Sci Int</source><year>2016</year><volume>261</volume><fpage>e5</fpage><lpage>e10</lpage><comment>DOI: 10.1016/j.forsciint.2016.02.024 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1016/j.forsciint.2016.02.024</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26934903">26934903</ext-link><comment> PubMed PMID: 26934903</comment><pub-id pub-id-type="pmid">26934903</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schep</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Slaughter</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>S</given-names></name><name name-style="western"><surname>Place</surname><given-names>R</given-names></name><name name-style="western"><surname>Watts</surname><given-names>M</given-names></name></person-group><article-title>Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues</article-title><source>Hum Exp Toxicol</source><year>2015</year><volume>34</volume><issue>5</issue><fpage>557</fpage><lpage>60</lpage><comment>DOI: 10.1177/0960327114550886 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1177/0960327114550886</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25233895">25233895</ext-link><comment> PubMed PMID: 25233895</comment><pub-id pub-id-type="pmid">25233895</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tait</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Caldicott</surname><given-names>D</given-names></name><name name-style="western"><surname>Mountain</surname><given-names>D</given-names></name><name name-style="western"><surname>Hill</surname><given-names>SL</given-names></name><name name-style="western"><surname>Lenton</surname><given-names>S</given-names></name></person-group><article-title>A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment</article-title><source>Clin Toxicol</source><year>2016</year><volume>54</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><comment>DOI: 10.3109/15563650.2015.1110590 PubMed PMID: </comment><pub-id pub-id-type="doi">10.3109/15563650.2015.1110590</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26567470">26567470</ext-link><comment> PubMed PMID: 26567470</comment></element-citation></ref><ref id="i2168-9709-9-2-93-b06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spaderna</surname><given-names>M</given-names></name><name name-style="western"><surname>Addy</surname><given-names>PH</given-names></name><name name-style="western"><surname>D'Souza</surname><given-names>DC</given-names></name></person-group><article-title>Spicing things up: synthetic cannabinoids</article-title><source>Psychopharmacol (Berl)</source><year>2013</year><volume>228</volume><issue>4</issue><fpage>525</fpage><lpage>40</lpage><comment>DOI: 10.1007/s00213-013-3188-4 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1007/s00213-013-3188-4</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/23836028">23836028</ext-link><comment> PubMed PMID: 23836028</comment></element-citation></ref><ref id="i2168-9709-9-2-93-b07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinotti</surname><given-names>G</given-names></name><name name-style="western"><surname>Santacroce</surname><given-names>R</given-names></name><name name-style="western"><surname>Papanti</surname><given-names>D</given-names></name><name name-style="western"><surname>Elgharably</surname><given-names>Y</given-names></name><name name-style="western"><surname>Prilutskaya</surname><given-names>M</given-names></name><name name-style="western"><surname>Corazza</surname><given-names>O</given-names></name></person-group><article-title>Synthetic cannabinoids: psychopharmacology, clinical aspects, psychotic onset</article-title><source>CNS Neurol Disord Drug Targets</source><year>2017</year><volume>16</volume><issue>5</issue><fpage>567</fpage><lpage>75</lpage><comment>DOI: 10.2174/1871527316666170413101839 PubMed PMID: </comment><pub-id pub-id-type="doi">10.2174/1871527316666170413101839</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/28412921">28412921</ext-link><comment> PubMed PMID: 28412921</comment><pub-id pub-id-type="pmid">28412921</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>S</given-names></name><name name-style="western"><surname>Fantegrossi</surname><given-names>WE</given-names></name></person-group><article-title>Pharmacological and toxicological effects of synthetic cannabinoids and their metabolites</article-title><source>Curr Top Behav Neurosci</source><year>2017</year><volume>32</volume><fpage>249</fpage><lpage>62</lpage><comment>DOI: 10.1007/7854_2016_60 PubMed PMID: 28012093 PubMed Central PMCID: </comment><pub-id pub-id-type="doi">10.1007/7854_2016_60</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/28012093">28012093</ext-link><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392241">PMC5392241</ext-link><comment> PubMed PMID: 28012093 PubMed Central PMCID: PMC5392241 ISBN: 978-3-319-52442-9</comment><pub-id pub-id-type="pmid">28012093</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behonick</surname><given-names>G</given-names></name><name name-style="western"><surname>Shanks</surname><given-names>KG</given-names></name><name name-style="western"><surname>Firchau</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Mathur</surname><given-names>G</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>CF</given-names></name><name name-style="western"><surname>Nashelsky</surname><given-names>M</given-names></name><etal/></person-group><article-title>Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22</article-title><source>J Anal Toxicol</source><year>2014</year><volume>38</volume><issue>8</issue><fpage>559</fpage><lpage>62</lpage><comment>DOI: 10.1093/jat/bku048 PubMed PMID: 24876364 PubMed Central PMCID: </comment><pub-id pub-id-type="doi">10.1093/jat/bku048</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24876364">24876364</ext-link><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334789">PMC4334789</ext-link><comment> PubMed PMID: 24876364 PubMed Central PMCID: PMC4334789</comment><pub-id pub-id-type="pmid">24876364</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fattore</surname><given-names>L</given-names></name></person-group><article-title>Synthetic cannabinoids&#x02014;further evidence supporting the relationship between cannabinoids and psychosis</article-title><source>Biol Psychiatry</source><year>2016</year><volume>79</volume><issue>7</issue><fpage>539</fpage><lpage>48</lpage><comment>DOI: 10.1016/j.biopsych.2016.02.001 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1016/j.biopsych.2016.02.001</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26970364">26970364</ext-link><comment> PubMed PMID: 26970364</comment><pub-id pub-id-type="pmid">26970364</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b11"><label>11</label><element-citation publication-type="web"><collab>US Drug Enforcement Administration [Internet]</collab><article-title>Drug scheduling</article-title><comment>[cited</comment><year>2018</year><comment>Nov 19]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.dea.gov/drug-scheduling">https://www.dea.gov/drug-scheduling</ext-link></comment></element-citation></ref><ref id="i2168-9709-9-2-93-b12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McIlroy</surname><given-names>G</given-names></name><name name-style="western"><surname>Ford</surname><given-names>L</given-names></name><name name-style="western"><surname>Khan</surname><given-names>JM</given-names></name></person-group><article-title>Acute myocardial infarction, associated with the use of a synthetic adamantyl-cannabinoid: a case report</article-title><source>BMC Pharmacol Toxicol</source><year>2016</year><volume>17</volume><fpage>2</fpage><comment>DOI: 10.1186/s40360-016-0045-1 PubMed PMID: 26772803 PubMed Central PMCID: </comment><pub-id pub-id-type="doi">10.1186/s40360-016-0045-1</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26772803">26772803</ext-link><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715335">PMC4715335</ext-link><comment> PubMed PMID: 26772803 PubMed Central PMCID: PMC4715335</comment><pub-id pub-id-type="pmid">26772803</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mercolini</surname><given-names>L</given-names></name><name name-style="western"><surname>Protti</surname><given-names>M</given-names></name></person-group><article-title>Biosampling strategies for emerging drugs of abuse: towards the future of toxicological and forensic analysis</article-title><source>J Pharm Biomed Analysis</source><year>2016</year><volume>130</volume><fpage>202</fpage><lpage>19</lpage><comment>DOI: 10.1016/j.jpba.2016.06.046 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1016/j.jpba.2016.06.046</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/27424495">27424495</ext-link><comment> PubMed PMID: 27424495</comment></element-citation></ref><ref id="i2168-9709-9-2-93-b14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hermanns-Clausen</surname><given-names>M</given-names></name><name name-style="western"><surname>Kneisel</surname><given-names>S</given-names></name><name name-style="western"><surname>Hutter</surname><given-names>M</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>B</given-names></name><name name-style="western"><surname>Auw&#x000e4;rter</surname><given-names>V</given-names></name></person-group><article-title>Acute intoxication by synthetic cannabinoids&#x02014;four case reports</article-title><source>Drug Test Analysis</source><year>2013</year><volume>5</volume><issue>9-10</issue><fpage>790</fpage><lpage>4</lpage><comment>DOI: 10.1002/dta.1483 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1002/dta.1483</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/23696237">23696237</ext-link><comment> PubMed PMID: 23696237</comment></element-citation></ref><ref id="i2168-9709-9-2-93-b15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pourmand</surname><given-names>A</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>P</given-names></name><name name-style="western"><surname>Mazer-Amirshahi</surname><given-names>M</given-names></name><name name-style="western"><surname>Shokoohi</surname><given-names>H</given-names></name></person-group><article-title>The evolving high: new designer drugs of abuse</article-title><source>Hum Exp Toxicol</source><year>2014</year><volume>33</volume><issue>10</issue><fpage>993</fpage><lpage>9</lpage><comment>DOI: 10.1177/0960327113514100 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1177/0960327113514100</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24501103">24501103</ext-link><comment> PubMed PMID: 24501103</comment><pub-id pub-id-type="pmid">24501103</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Traynor</surname><given-names>K</given-names></name></person-group><article-title>Illinois hospitals cope with outbreak of bleeding linked to tainted cannabinoids</article-title><source>Am J Health Syst Pharm</source><year>2018</year><volume>75</volume><issue>11</issue><fpage>728</fpage><lpage>32</lpage><comment>DOI: 10.2146/news180032 PubMed PMID: </comment><pub-id pub-id-type="doi">10.2146/news180032</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/29695484">29695484</ext-link><comment> PubMed PMID: 29695484</comment><pub-id pub-id-type="pmid">29695484</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b17"><label>17</label><element-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Herman</surname><given-names>AO</given-names></name></person-group><article-title>CDC warns about potentially life-threatening bleeding with synthetic cannabinoids</article-title><comment>[cited</comment><year>2018</year><comment>Nov 18]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.jwatch.org/fw114047/2018/04/09/cdc-warns-about-potentially-life-threatening-bleeding">https://www.jwatch.org/fw114047/2018/04/09/cdc-warns-about-potentially-life-threatening-bleeding</ext-link></comment></element-citation></ref><ref id="i2168-9709-9-2-93-b18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hermanns-Clausen</surname><given-names>M</given-names></name><name name-style="western"><surname>M&#x000fc;ller</surname><given-names>D</given-names></name><name name-style="western"><surname>Kithinji</surname><given-names>J</given-names></name><name name-style="western"><surname>Angerer</surname><given-names>V</given-names></name><name name-style="western"><surname>Franz</surname><given-names>F</given-names></name><name name-style="western"><surname>Eyer</surname><given-names>F</given-names></name><etal/></person-group><article-title>Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA</article-title><source>Clin Toxicol</source><year>2018</year><volume>56</volume><issue>6</issue><fpage>404</fpage><lpage>11</lpage><comment>DOI: 10.1080/15563650.2017.1393082 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1080/15563650.2017.1393082</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/29072524">29072524</ext-link><comment> PubMed PMID: 29072524</comment></element-citation></ref><ref id="i2168-9709-9-2-93-b19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomiyama</surname><given-names>K</given-names></name><name name-style="western"><surname>Funada</surname><given-names>M</given-names></name></person-group><article-title>Cytotoxicity of synthetic cannabinoids on primary neuronal cells of the forebrain: the involvement of cannabinoid CB1 receptors and apoptotic cell death</article-title><source>Toxicol Appl Pharmacol</source><year>2014</year><volume>274</volume><issue>1</issue><fpage>17</fpage><lpage>23</lpage><comment>DOI: 10.1016/j.taap.2013.10.028 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1016/j.taap.2013.10.028</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24211273">24211273</ext-link><comment> PubMed PMID: 24211273</comment><pub-id pub-id-type="pmid">24211273</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wood</surname><given-names>DM</given-names></name><name name-style="western"><surname>Hill</surname><given-names>SL</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>SHL</given-names></name><name name-style="western"><surname>Dargan</surname><given-names>PI</given-names></name></person-group><article-title>Using poisons information service data to assess the acute harms associated with novel psychoactive substances</article-title><source>Drug Test Analysis</source><year>2014</year><volume>6</volume><issue>7-8</issue><fpage>850</fpage><lpage>60</lpage><comment>DOI: 10.1002/dta.1671 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1002/dta.1671</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24832864">24832864</ext-link><comment> PubMed PMID: 24832864</comment></element-citation></ref><ref id="i2168-9709-9-2-93-b21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>RPK</given-names></name><name name-style="western"><surname>Tang</surname><given-names>MHY</given-names></name><name name-style="western"><surname>Leung</surname><given-names>SC</given-names></name><name name-style="western"><surname>Chong</surname><given-names>YK</given-names></name><name name-style="western"><surname>Tsui</surname><given-names>MSH</given-names></name><name name-style="western"><surname>Mak</surname><given-names>TWL</given-names></name></person-group><article-title>Supraventricular tachycardia and acute confusion following ingestion of e-cigarette fluid containing AB-FUBINACA and ADB-FUBINACA: a case report with quantitative analysis of serum drug concentrations</article-title><source>Clin Toxicol</source><year>2017</year><volume>55</volume><issue>7</issue><fpage>662</fpage><lpage>7</lpage><comment>DOI: 10.1080/15563650.2017.1307385 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1080/15563650.2017.1307385</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/28393558">28393558</ext-link><comment> PubMed PMID: 28393558</comment></element-citation></ref><ref id="i2168-9709-9-2-93-b22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davidson</surname><given-names>C</given-names></name><name name-style="western"><surname>Opacka-Juffry</surname><given-names>J</given-names></name><name name-style="western"><surname>Arevalo-Martin</surname><given-names>A</given-names></name><name name-style="western"><surname>Garcia-Ovejero</surname><given-names>D</given-names></name><name name-style="western"><surname>Molina-Holgado</surname><given-names>E</given-names></name><name name-style="western"><surname>Molina-Holgado</surname><given-names>F</given-names></name></person-group><article-title>Spicing up pharmacology: a review of synthetic cannabinoids from structure to adverse events</article-title><source>Adv Pharmacol</source><year>2017</year><volume>80</volume><fpage>135</fpage><lpage>68</lpage><comment>DOI: 10.1016/bs.apha.2017.05.001 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1016/bs.apha.2017.05.001</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/28826533">28826533</ext-link><comment> PubMed PMID: 28826533</comment><pub-id pub-id-type="pmid">28826533</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keskin</surname><given-names>M</given-names></name></person-group><article-title>Acute myocardial infarction and ischemic stroke coexistence due to marijuana abuse in an adolescent</article-title><source>Anatol J Cardiol</source><year>2016</year><volume>16</volume><issue>7</issue><fpage>542</fpage><lpage>3</lpage><comment>DOI: 10.14744/AnatolJCardiol.2016.6978 PubMed PMID: 27389155 PubMed Central PMCID: </comment><pub-id pub-id-type="doi">10.14744/AnatolJCardiol.2016.6978</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/27389155">27389155</ext-link><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331404">PMC5331404</ext-link><comment> PubMed PMID: 27389155 PubMed Central PMCID: PMC5331404</comment><pub-id pub-id-type="pmid">27389155</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westin</surname><given-names>AA</given-names></name><name name-style="western"><surname>Frost</surname><given-names>J</given-names></name><name name-style="western"><surname>Brede</surname><given-names>WR</given-names></name><name name-style="western"><surname>Gundersen</surname><given-names>POM</given-names></name><name name-style="western"><surname>Einvik</surname><given-names>S</given-names></name><name name-style="western"><surname>Aarset</surname><given-names>H</given-names></name><etal/></person-group><article-title>Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA</article-title><source>J Anal Toxicol</source><year>2015</year><volume>40</volume><issue>1</issue><fpage>86</fpage><lpage>7</lpage><comment>DOI: 10.1093/jat/bkv110 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1093/jat/bkv110</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26353925">26353925</ext-link><comment> PubMed PMID: 26353925</comment><pub-id pub-id-type="pmid">26353925</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moritz</surname><given-names>E</given-names></name><name name-style="western"><surname>Austin</surname><given-names>C</given-names></name><name name-style="western"><surname>Wahl</surname><given-names>M</given-names></name><name name-style="western"><surname>DesLauriers</surname><given-names>C</given-names></name><name name-style="western"><surname>Navon</surname><given-names>L</given-names></name><name name-style="western"><surname>Walblay</surname><given-names>K</given-names></name><etal/></person-group><article-title>Notes from the field: outbreak of severe illness linked to the vitamin K antagonist brodifacoum and use of synthetic cannabinoids&#x02014;Illinois, March-April 2018</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2018</year><volume>67</volume><issue>21</issue><fpage>607</fpage><lpage>8</lpage><comment>DOI: 10.15585/mmwr.mm6721a4 PubMed PMID: 29851941 PubMed Central PMCID: </comment><pub-id pub-id-type="doi">10.15585/mmwr.mm6721a4</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/29851941">29851941</ext-link><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038901">PMC6038901</ext-link><comment> PubMed PMID: 29851941 PubMed Central PMCID: PMC6038901</comment><pub-id pub-id-type="pmid">29851941</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panigrahi</surname><given-names>B</given-names></name><name name-style="western"><surname>Jones</surname><given-names>BC</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>SP</given-names></name></person-group><article-title>Brodifacoum-contaminated synthetic marijuana: clinical and radiologic manifestations of a public health outbreak causing life-threatening coagulopathy</article-title><source>Emerg Radiol</source><year>2018</year><volume>25</volume><issue>6</issue><fpage>715</fpage><lpage>8</lpage><comment>DOI: 10.1007/s10140-018-1628-5 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1007/s10140-018-1628-5</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/30022308">30022308</ext-link><comment> PubMed PMID: 30022308</comment><pub-id pub-id-type="pmid">30022308</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussain</surname><given-names>N</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>F</given-names></name><name name-style="western"><surname>Haque</surname><given-names>D</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>S</given-names></name><name name-style="western"><surname>Jesudas</surname><given-names>R</given-names></name></person-group><article-title>An outbreak of brodifacoum coagulopathy due to synthetic marijuana in central Illinois</article-title><source>Mayo Clin Proc</source><year>2018</year><volume>93</volume><issue>7</issue><fpage>957</fpage><lpage>8</lpage><comment>DOI: 10.1016/j.mayocp.2018.05.005 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1016/j.mayocp.2018.05.005</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/29976379">29976379</ext-link><comment> PubMed PMID: 29976379</comment><pub-id pub-id-type="pmid">29976379</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aydin</surname><given-names>S</given-names></name><name name-style="western"><surname>Yuksel</surname><given-names>O</given-names></name><name name-style="western"><surname>Aydin</surname><given-names>AE</given-names></name><name name-style="western"><surname>Kizilkilic</surname><given-names>O</given-names></name><name name-style="western"><surname>Celik</surname><given-names>SE</given-names></name></person-group><article-title>Intracerebral hemorrhage with multiple intracranial arterial stenoses in a synthetic cannabinoid &#x0201c;spice&#x0201d; user</article-title><source>Asian J Neurosurg</source><year>2018</year><volume>13</volume><issue>2</issue><fpage>522</fpage><comment>DOI: 10.4103/ajns.AJNS_48_16 PubMed PMID: 29682077 PubMed Central PMCID: </comment><pub-id pub-id-type="doi">10.4103/ajns.AJNS_48_16</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/29682077">29682077</ext-link><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898148">PMC5898148</ext-link><comment> PubMed PMID: 29682077 PubMed Central PMCID: PMC5898148</comment><pub-id pub-id-type="pmid">29682077</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rose</surname><given-names>DZ</given-names></name><name name-style="western"><surname>Guerrero</surname><given-names>WR</given-names></name><name name-style="western"><surname>Mokin</surname><given-names>MV</given-names></name><name name-style="western"><surname>Gooch</surname><given-names>CL</given-names></name><name name-style="western"><surname>Bozeman</surname><given-names>AC</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Hemorrhagic stroke following use of the synthetic marijuana &#x0201c;spice&#x0201d;</article-title><source>Neurology</source><year>2015</year><volume>85</volume><issue>13</issue><fpage>1177</fpage><lpage>9</lpage><comment>DOI: 10.1212/WNL.0000000000001973 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1212/WNL.0000000000001973</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26320200">26320200</ext-link><comment> PubMed PMID: 26320200</comment><pub-id pub-id-type="pmid">26320200</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolff</surname><given-names>V</given-names></name><name name-style="western"><surname>Jouanjus</surname><given-names>E</given-names></name></person-group><article-title>Strokes are possible complications of cannabinoids use</article-title><source>Epilepsy Behav</source><year>2017</year><volume>70</volume><fpage>355</fpage><lpage>63</lpage><comment>DOI: 10.1016/j.yebeh.2017.01.031 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1016/j.yebeh.2017.01.031</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/28237318">28237318</ext-link><comment> PubMed PMID: 28237318</comment><pub-id pub-id-type="pmid">28237318</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moeller</surname><given-names>S</given-names></name><name name-style="western"><surname>L&#x000fc;cke</surname><given-names>C</given-names></name><name name-style="western"><surname>Struffert</surname><given-names>T</given-names></name><name name-style="western"><surname>Schwarze</surname><given-names>B</given-names></name><name name-style="western"><surname>Gerner</surname><given-names>ST</given-names></name><name name-style="western"><surname>Schwab</surname><given-names>S</given-names></name><etal/></person-group><article-title>Ischemic stroke associated with the use of a synthetic cannabinoid (spice)</article-title><source>Asian J Psychiatry</source><year>2017</year><volume>25</volume><fpage>127</fpage><lpage>30</lpage><comment>DOI: 10.1016/j.ajp.2016.10.019 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1016/j.ajp.2016.10.019</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/28262132">28262132</ext-link><comment> PubMed PMID: 28262132</comment></element-citation></ref><ref id="i2168-9709-9-2-93-b32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernson-Leung</surname><given-names>ME</given-names></name><name name-style="western"><surname>Leung</surname><given-names>LY</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name></person-group><article-title>Synthetic cannabis and acute ischemic stroke</article-title><source>J Stroke Cerebrovasc Dis</source><year>2014</year><volume>23</volume><issue>5</issue><fpage>1239</fpage><lpage>41</lpage><comment>DOI: 10.1016/j.jstrokecerebrovasdis.2013.07.030 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2013.07.030</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24119618">24119618</ext-link><comment> PubMed PMID: 24119618</comment><pub-id pub-id-type="pmid">24119618</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashton</surname><given-names>JC</given-names></name></person-group><article-title>Synthetic cannabinoids as drugs of abuse</article-title><source>Curr Drug Abuse Rev</source><year>2012</year><volume>5</volume><issue>2</issue><fpage>158</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.2174/1874473711205020158</pub-id><pub-id pub-id-type="pmid">22530798</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rojek</surname><given-names>S</given-names></name><name name-style="western"><surname>K&#x00142;ys</surname><given-names>M</given-names></name><name name-style="western"><surname>Maci&#x000f3;w-G&#x00142;&#x00105;b</surname><given-names>M</given-names></name><name name-style="western"><surname>Kula</surname><given-names>K</given-names></name></person-group><article-title>A new challenge in forensic toxicology exemplified by a case of murder under the influence of a synthetic cannabinoid&#x02014;AM-2201</article-title><source>Leg Medicine</source><year>2017</year><volume>27</volume><fpage>25</fpage><lpage>31</lpage><comment>DOI: 10.1016/j.legalmed.2017.06.004 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1016/j.legalmed.2017.06.004</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/28668480">28668480</ext-link><comment> PubMed PMID: 28668480</comment></element-citation></ref><ref id="i2168-9709-9-2-93-b35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaenicke</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Pogoda</surname><given-names>W</given-names></name><name name-style="western"><surname>Paulke</surname><given-names>A</given-names></name><name name-style="western"><surname>Wunder</surname><given-names>C</given-names></name><name name-style="western"><surname>Toennes</surname><given-names>SW</given-names></name></person-group><article-title>Retrospective analysis of synthetic cannabinoids in serum samples&#x02014;epidemiology and consumption patterns</article-title><source>Forensic Sci Int</source><year>2014</year><volume>242</volume><fpage>81</fpage><lpage>7</lpage><comment>DOI: 10.1016/j.forsciint.2014.06.010 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1016/j.forsciint.2014.06.010</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25050839">25050839</ext-link><comment> PubMed PMID: 25050839</comment><pub-id pub-id-type="pmid">25050839</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kazory</surname><given-names>A</given-names></name><name name-style="western"><surname>Aiyer</surname><given-names>R</given-names></name></person-group><article-title>Synthetic marijuana and acute kidney injury: an unforeseen association</article-title><source>Clin Kidney J</source><year>2013</year><volume>6</volume><issue>3</issue><fpage>330</fpage><lpage>3</lpage><comment>DOI: 10.1093/ckj/sft047 PubMed PMID: 26064495 PubMed Central PMCID: </comment><pub-id pub-id-type="doi">10.1093/ckj/sft047</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26064495">26064495</ext-link><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400490">PMC4400490</ext-link><comment> PubMed PMID: 26064495 PubMed Central PMCID: PMC4400490</comment><pub-id pub-id-type="pmid">26064495</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monte</surname><given-names>AA</given-names></name><name name-style="western"><surname>Calello</surname><given-names>DP</given-names></name><name name-style="western"><surname>Gerona</surname><given-names>RR</given-names></name><name name-style="western"><surname>Hamad</surname><given-names>E</given-names></name><name name-style="western"><surname>Campleman</surname><given-names>SL</given-names></name><name name-style="western"><surname>Brent</surname><given-names>J</given-names></name><etal/></person-group><article-title>Characteristics and treatment of patients with clinical illness due to synthetic cannabinoid inhalation reported by medical toxicologists: a ToxIC Database Study</article-title><source>J Med Toxicol</source><year>2017</year><volume>13</volume><issue>2</issue><fpage>146</fpage><lpage>52</lpage><comment>DOI: 10.1007/s13181-017-0605-9 PubMed PMID: 28397128 PubMed Central PMCID: </comment><pub-id pub-id-type="doi">10.1007/s13181-017-0605-9</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/28397128">28397128</ext-link><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440319">PMC5440319</ext-link><comment> PubMed PMID: 28397128 PubMed Central PMCID: PMC5440319</comment><pub-id pub-id-type="pmid">28397128</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buser</surname><given-names>GL</given-names></name><name name-style="western"><surname>Gerona</surname><given-names>RR</given-names></name><name name-style="western"><surname>Horowitz</surname><given-names>BZ</given-names></name><name name-style="western"><surname>Vian</surname><given-names>KP</given-names></name><name name-style="western"><surname>Troxell</surname><given-names>ML</given-names></name><name name-style="western"><surname>Hendrickson</surname><given-names>RG</given-names></name><etal/></person-group><article-title>Acute kidney injury associated with smoking synthetic cannabinoid</article-title><source>Clin Toxicol</source><year>2014</year><volume>52</volume><issue>7</issue><fpage>664</fpage><lpage>73</lpage><comment>DOI: 10.3109/15563650.2014.932365 PubMed PMID: </comment><pub-id pub-id-type="doi">10.3109/15563650.2014.932365</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25089722">25089722</ext-link><comment> PubMed PMID: 25089722</comment></element-citation></ref><ref id="i2168-9709-9-2-93-b39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pintori</surname><given-names>N</given-names></name><name name-style="western"><surname>Loi</surname><given-names>B</given-names></name><name name-style="western"><surname>Mereu</surname><given-names>M</given-names></name></person-group><article-title>Synthetic cannabinoids</article-title><source>Behav Pharmacol</source><year>2017</year><volume>28</volume><issue>6</issue><fpage>409</fpage><lpage>19</lpage><comment>DOI: 10.1097/FBP.0000000000000323 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1097/FBP.0000000000000323</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/28692429">28692429</ext-link><comment> PubMed PMID: 28692429</comment><pub-id pub-id-type="pmid">28692429</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozturk</surname><given-names>S</given-names></name><name name-style="western"><surname>Ozturk</surname><given-names>YE</given-names></name><name name-style="western"><surname>Yeter</surname><given-names>O</given-names></name><name name-style="western"><surname>Alpertunga</surname><given-names>B</given-names></name></person-group><article-title>Application of a validated LC&#x02013;MS/MS method for JWH-073 and its metabolites in blood and urine in real forensic cases</article-title><source>Forensic Sci Int</source><year>2015</year><volume>257</volume><fpage>165</fpage><lpage>71</lpage><comment>DOI: 10.1016/j.forsciint.2015.08.013 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1016/j.forsciint.2015.08.013</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26360591">26360591</ext-link><comment> PubMed PMID: 26360591</comment><pub-id pub-id-type="pmid">26360591</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kemp</surname><given-names>AM</given-names></name><name name-style="western"><surname>Clark</surname><given-names>MS</given-names></name><name name-style="western"><surname>Dobbs</surname><given-names>T</given-names></name><name name-style="western"><surname>Galli</surname><given-names>R</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>J</given-names></name><name name-style="western"><surname>Cox</surname><given-names>R</given-names></name></person-group><article-title>Top 10 facts you need to know about synthetic cannabinoids: not so nice spice</article-title><source>Am J Med</source><year>2016</year><volume>129</volume><issue>3</issue><fpage>240</fpage><lpage>244.e1</lpage><comment>DOI: 10.1016/j.amjmed.2015.10.008 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1016/j.amjmed.2015.10.008</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26522795">26522795</ext-link><comment> PubMed PMID: 26522795</comment><pub-id pub-id-type="pmid">26522795</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fantegrossi</surname><given-names>WE</given-names></name><name name-style="western"><surname>Moran</surname><given-names>JH</given-names></name><name name-style="western"><surname>Radominska-Pandya</surname><given-names>A</given-names></name><name name-style="western"><surname>Prather</surname><given-names>PL</given-names></name></person-group><article-title>Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to &#x00394;9-THC: mechanism underlying greater toxicity?</article-title><source>Life Sci</source><year>2014</year><volume>97</volume><issue>1</issue><fpage>45</fpage><lpage>54</lpage><comment>DOI: 10.1016/j.lfs.2013.09.017 PubMed PMID: 24084047 PubMed Central PMCID: </comment><pub-id pub-id-type="doi">10.1016/j.lfs.2013.09.017</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24084047">24084047</ext-link><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3945037">PMC3945037</ext-link><comment> PubMed PMID: 24084047 PubMed Central PMCID: PMC3945037</comment><pub-id pub-id-type="pmid">24084047</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chimalakonda</surname><given-names>KC</given-names></name><name name-style="western"><surname>Seely</surname><given-names>KA</given-names></name><name name-style="western"><surname>Bratton</surname><given-names>SM</given-names></name><name name-style="western"><surname>Brents</surname><given-names>LK</given-names></name><name name-style="western"><surname>Moran</surname><given-names>CL</given-names></name><name name-style="western"><surname>Endres</surname><given-names>GW</given-names></name><etal/></person-group><article-title>Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/spice: identification of novel cannabinoid receptor ligands</article-title><source>Drug Metabolism Dispos</source><year>2012</year><volume>40</volume><issue>11</issue><fpage>2174</fpage><lpage>84</lpage><comment>DOI: 10.1124/dmd.112.047530 PubMed PMID: 22904561 PubMed Central PMCID: </comment><pub-id pub-id-type="doi">10.1124/dmd.112.047530</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22904561">22904561</ext-link><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477201">PMC3477201</ext-link><comment> PubMed PMID: 22904561 PubMed Central PMCID: PMC3477201</comment></element-citation></ref><ref id="i2168-9709-9-2-93-b44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>BB</given-names></name><name name-style="western"><surname>Bayard</surname><given-names>C</given-names></name><name name-style="western"><surname>Larson</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Zarwell</surname><given-names>LW</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>RA</given-names></name></person-group><article-title>Retrospective analysis of synthetic cannabinoid metabolites in urine of individuals suspected of driving impaired</article-title><source>J Anal Toxicol</source><year>2015</year><volume>40</volume><issue>2</issue><fpage>89</fpage><lpage>96</lpage><comment>DOI: 10.1093/jat/bkv136 PubMed PMID: </comment><pub-id pub-id-type="doi">10.1093/jat/bkv136</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/26687103">26687103</ext-link><comment> PubMed PMID: 26687103</comment><pub-id pub-id-type="pmid">26687103</pub-id></element-citation></ref><ref id="i2168-9709-9-2-93-b45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#x000d6;zt&#x000fc;rk</surname><given-names>E</given-names></name><name name-style="western"><surname>Oral</surname><given-names>A</given-names></name><name name-style="western"><surname>&#x000d6;zdemir</surname><given-names>M</given-names></name><name name-style="western"><surname>Bambul</surname><given-names>N</given-names></name></person-group><article-title>Synthetic marijuana &#x0201c;K2&#x0201d; induced ITP</article-title><source>Platelets</source><year>2015</year><volume>26</volume><issue>3</issue><fpage>258</fpage><lpage>9</lpage><comment>DOI: 10.3109/09537104.2014.898263 PubMed PMID: </comment><pub-id pub-id-type="doi">10.3109/09537104.2014.898263</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24749892">24749892</ext-link><comment> PubMed PMID: 24749892</comment><pub-id pub-id-type="pmid">24749892</pub-id></element-citation></ref></ref-list></back></article>